Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | The prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma

Nicholas Bingham • 28 Sep 2023
IMS 2023
Multiple Myeloma

Nicholas Bingham, MBBS, FRACP, FRCPA, Alfred Health & Monash University, Melbourne, Australia, discusses the prognostic and therapeutic value of liquid biopsy in multiple myeloma, and further highlights how this approach may be used to highlight mutations in cell-free DNA (cfDNA) and better predict patient response to therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Celgene/BMS – travel support
Janssen – honorarium

More from Nicholas Bingham

The role of small nucleotide, copy number and structural variants in extramedullary myeloma 2:00
The role of small nucleotide, copy number and structural variants in extramedullary myeloma
Nicholas Bingham • 28 Sep 2023
Evaluating the sensitivity of liquid biopsy in patients with extramedullary multiple myeloma 1:23
Evaluating the sensitivity of liquid biopsy in patients with extramedullary multiple myeloma
Nicholas Bingham • 28 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals